IJR News - today's news from every side

IJR News - today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Genius — OpenServe

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

OpenServe Drive OpenServe Inbox OpenServe Write OpenServe Studio OpenServe Projects OpenServe Focus OpenServe Mindmaps Teams OpenServe CRM Site Builder Whiteboard

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms About Company Solutions Free assessment Investors Get the app Contact

News

Home
Popular
Congress

Genius — OpenServe

Veradermics Reports Hair-Loss Drug Meets Phase 3 Endpoints — Oct 19, 2026Veradermics said its extended-release oral minoxidil met all primary and secondary endpoints in a Phase 3 trial for male pattern hair loss, with six-month hair-count gains of 28.6 and 36.4 hairs/cm² for once- and twice-daily dosing, versus 6.6 with placebo. No treatment-related serious or cardiac safety events were reported, though peripheral edema and excess hair growth occurred in some participants; longer-term and female-trial results remain pending.

0